KRAS and cancer: The best therapeutic targets are the neoantigens that are produced by high-prevalence cancer driver genes and at the same time can be presented by high-frequency HLA alleles on the host’s cancer cell surface, such as the neoantigens derived from TP53 and K-Ras mutant proteins and presented by the predominant HLA-A2 allele [17,18].